What determines mortality in malignant pheochromocytoma? : report of a case with eighteen-year survival and review of the literature

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAndrade, Matheus de Oliveira-
Autor(es): dc.creatorCunha, Vinícius Santos da-
Autor(es): dc.creatorOliveira, Dayana Carla de-
Autor(es): dc.creatorMoraes, Olívia Laquis de-
Autor(es): dc.creatorPorto, Adriana Lofrano-
Data de aceite: dc.date.accessioned2024-10-23T16:26:31Z-
Data de disponibilização: dc.date.available2024-10-23T16:26:31Z-
Data de envio: dc.date.issued2019-01-02-
Data de envio: dc.date.issued2019-01-02-
Data de envio: dc.date.issued2018-
Fonte completa do material: dc.identifierhttp://repositorio.unb.br/handle/10482/33730-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.20945/2359-3997000000033-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/908560-
Descrição: dc.descriptionPheochromocytoma (PCC) is a tumor derived from adrenomedullary chromaffin cells. Prognosis of malignant PCC is generally poor due to local recurrence or metastasis. We aim to report a case of malignant PCC with 18-year survival and discuss which factors may be related to mortality and long-term survival in malignant pheochromocytoma. The patient, a 45-year-old man, reported sustained arterial hypertension with paroxysmal episodes of tachycardia, associated with head and neck burning sensation, and hand and foot tremors. Diagnosis of PCC was established biochemically and a tumor with infiltration of renal parenchyma was resected. No genetic mutation or copy number variations were identified in SDHB, SDHD, SDHC, MAX and VHL. Over 18 years, tumor progression was managed with 131I-MIBG (iodine-metaiodobenzylguanidine) and 177Lutetium-octreotate therapy. Currently, the patient is asymptomatic and presents sustained stable disease, despite the presence of lung, para-aortic lymph nodes and femoral metastases. Adequate response to treatment with control of tumor progression, absence of significant cardiovascular events and other neoplasms, and lack of mutations in the main predisposing genes reported so far may be factors possibly associated with the prolonged survival in this case. Early diagnosis and life-long follow-up in patients with malignant pheochromocytoma are known to be crucial in improving survival.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Publicador: dc.publisherSociedade Brasileira de Endocrinologia e Metabologia-
Direitos: dc.rightsAcesso Aberto-
Direitos: dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.-
Título: dc.titleWhat determines mortality in malignant pheochromocytoma? : report of a case with eighteen-year survival and review of the literature-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional – UNB

Não existem arquivos associados a este item.